Major depressive disorder trials recruiting in Connecticut

All Major depressive disorder trials nationally

Cities in Connecticut

Recruiting trials in Connecticut

• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
  NCT06775379 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Connecticut: Cromwell
• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
  NCT07076407 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Connecticut: Hartford
• A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT07196501 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• Imaging Depression in Parkinson's Disease
  NCT06402955 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female) · Connecticut: New Haven
• Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06966401 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: Cromwell, Farmington
• NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06963021 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: Cromwell, Farmington
• Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
  NCT06633016 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Connecticut: Cromwell
• Study of ALTO-300 in MDD
  NCT05922878 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Connecticut: Norwalk
• Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
  NCT05850689 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Connecticut: Farmington
• The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
  NCT05786066 · Phase: Phase 2 · Ages: 21 Years to 65 Years · Sex: All (male and female) · Connecticut: West Haven
• Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
  NCT06547489 · Phase: Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female) · Connecticut: Farmington